TD Cowen analyst Brendan Smith named Twist Bioscience (TWST) a Best Idea for 2025 while keeping a Buy rating on the shares with a $58 price target The company’s solid fiscal 2025 revenue and margin guidance builds on the 2024 beat and should reassure investors that its growth is durable and margins will keep improving, the analyst tells investors in a research note. The firm believes Twist’s execution should drive the stock’s 16% short interest down as next-generation sequencing continues to drive growth.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Twist Bioscience price target raised to $54 from $50 at Scotiabank
- Twist Bioscience price target raised to $48 from $46 at Baird
- Twist Bioscience Reports Record Revenue in 2024
- Twist Bioscience price target lowered to $52 from $55 at Barclays
- Spirit enters into bankruptcy proceedings, CVS names new directors: Morning Buzz